First AD

Second AD

Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.

She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.

Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.

Adjuvant and Neoadjuvant Therapy in Melanoma

Immune-Modulating Antibodies for Melanoma Treatment

Emerging Therapies in the Treatment of Melanoma

Uveal Melanoma

Skin Cancer

CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.

CURE Speaking Out

AIM at Melanoma

Is your organization missing from this list? Reach out to Danielle Cann, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: 

Advocacy Groups

On behalf of AiM at Melanoma, Drs. Jeffrey Farma and Sunandana Chandra discuss current and future treatment options for melanoma, including a rare subtype.

Latest News